On July 25, the US Food and Drug Administration (FDA) approved alirocumab (Praluent), the first in a new class, the proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors. Approval of a second medication in the class is expected shortly. The injected medications are used to treat patients with hyperlipidemia, and early results suggest these drugs have a powerful effect on levels of low-density lipoprotein cholesterol (LDL-C), likely more potent than statins.1 Although evidence continues to accumulate, the class appears to represent an important new development in hyperlipidemia management.
Shrank WH, Barlow JF, Brennan TA. New Therapies in the Treatment of High CholesterolAn Argument to Return to Goal-Based Lipid Guidelines. JAMA. 2015;314(14):1443-1444. doi:10.1001/jama.2015.10017